These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 25608415)

  • 1. [Modern therapy of prostate cancer].
    Kretschmer A; Stief C; Gratzke C
    MMW Fortschr Med; 2014 Dec; 156(21-22):71-3. PubMed ID: 25608415
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Adverse Pathology and Undetectable Ultrasensitive Prostate-Specific Antigen after Radical Prostatectomy: Is Adjuvant Radiation Warranted?
    Taneja SS
    J Urol; 2015 Dec; 194(6):1631-2. PubMed ID: 26582665
    [No Abstract]   [Full Text] [Related]  

  • 3. Is undetectable prostate-specific antigen always reliable to rule out prostate cancer recurrence after radical prostatectomy?
    Schriefer P; Steurer S; Huland H; Graefen M
    J Clin Oncol; 2012 Nov; 30(32):e341-4. PubMed ID: 23032622
    [No Abstract]   [Full Text] [Related]  

  • 4. [Management of rising PSA after total prostatectomy].
    Zerbib M
    Ann Urol (Paris); 2007 Oct; 41 Suppl 3():S73-6. PubMed ID: 18297904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usefulness of J-CAPRA score for high-risk prostate cancer patients treated with carbon ion radiotherapy plus androgen deprivation therapy.
    Akakura K; Tsuji H; Suzuki H; Ichikawa T; Ishikawa H; Okada T; Kamada T; Harada M; Tsujii H; Shimazaki J
    Jpn J Clin Oncol; 2014 Apr; 44(4):360-5. PubMed ID: 24585931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes and Prognostic Factors in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Recurrence after Radical Prostatectomy.
    Ravi P; Karnes RJ; Rangel LJ; Pagliaro LC
    J Urol; 2018 Nov; 200(5):1075-1081. PubMed ID: 29709664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Far remote results of radical prostatectomy in patients suffering localized and locally advanced prostatic cancer].
    Grigorenko VN; Shamraev SN; Danilets RO; Bardin AV; Gurzhenko AIu; Pereta LV
    Klin Khir; 2014 Mar; (3):44-8. PubMed ID: 25098000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anatomical Patterns of Recurrence Following Biochemical Relapse in the Dose Escalation Era of External Beam Radiotherapy for Prostate Cancer.
    Zumsteg ZS; Spratt DE; Romesser PB; Pei X; Zhang Z; Kollmeier M; McBride S; Yamada Y; Zelefsky MJ
    J Urol; 2015 Dec; 194(6):1624-30. PubMed ID: 26165583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of adjuvant androgen deprivation therapy after radical prostatectomy on the survival of patients with pathological T3b prostate cancer.
    Siddiqui SA; Boorjian SA; Blute ML; Rangel LJ; Bergstralh EJ; Karnes RJ; Frank I
    BJU Int; 2011 Feb; 107(3):383-8. PubMed ID: 21265985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upfront androgen deprivation therapy with salvage radiation may improve biochemical outcomes in prostate cancer patients with post-prostatectomy rising PSA.
    Jang JW; Hwang WT; Guzzo TJ; Wein AJ; Haas NB; Both S; Vapiwala N
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1493-9. PubMed ID: 22401922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elective pelvic versus prostate bed-only salvage radiotherapy following radical prostatectomy: A propensity score-matched analysis.
    Song C; Kang HC; Kim JS; Eom KY; Kim IA; Chung JB; Hong SK; Byun SS; Lee SE
    Strahlenther Onkol; 2015 Oct; 191(10):801-9. PubMed ID: 26159555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
    Carrie C; Hasbini A; de Laroche G; Richaud P; Guerif S; Latorzeff I; Supiot S; Bosset M; Lagrange JL; Beckendorf V; Lesaunier F; Dubray B; Wagner JP; N'Guyen TD; Suchaud JP; Créhange G; Barbier N; Habibian M; Ferlay C; Fourneret P; Ruffion A; Dussart S
    Lancet Oncol; 2016 Jun; 17(6):747-756. PubMed ID: 27160475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Active surveillance for favorable-risk prostate cancer: what are the results and how safe is it?
    Klotz L
    Curr Urol Rep; 2007 Sep; 8(5):341-4. PubMed ID: 17880830
    [No Abstract]   [Full Text] [Related]  

  • 15. [Adjuvant medical treatment or radiotherapy following radical prostatectomy or curative radiotherapy].
    Guy L
    Bull Cancer; 2007 Jul; 94(7 Suppl):F15-20. PubMed ID: 17845989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contemporary survival results and the role of radiation therapy in patients with node negative seminal vesicle invasion following radical prostatectomy.
    Eggener SE; Roehl KA; Smith ND; Antenor JA; Han M; Catalona WJ
    J Urol; 2005 Apr; 173(4):1150-5. PubMed ID: 15758725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nodal Clearance Rate and Long-Term Efficacy of Individualized Sentinel Node-Based Pelvic Intensity Modulated Radiation Therapy for High-Risk Prostate Cancer.
    Müller AC; Eckert F; Paulsen F; Zips D; Stenzl A; Schilling D; Alber M; Bares R; Martus P; Weckermann D; Belka C; Ganswindt U
    Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):263-71. PubMed ID: 26853335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Locally advanced prostate cancer: definition, prognosis and treatment].
    Plantade A; Massard C; de Crevoisier R; Fizazi K
    Bull Cancer; 2007 Jul; 94(7 Suppl):F50-61. PubMed ID: 17845994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three linked nomograms for predicting biochemical failure in prostate cancer treated with radiotherapy plus androgen deprivation therapy.
    López-Torrecilla J; Boladeras A; Cabeza MA; Zapatero A; Jove J; Esteban LM; Henriquez I; Casaña M; González-San Segundo C; Gómez-Caamaño A; Mengual JL; Hervás A; Muñoz JL; Sanz G
    Strahlenther Onkol; 2015 Oct; 191(10):792-800. PubMed ID: 26156249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The role of PSA in diagnosis of prostate cancer and its recurrence].
    Vergho DC; Heine K; Wolff JM
    Pathologe; 2005 Nov; 26(6):473-8. PubMed ID: 16215709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.